Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination

DRUG2 trials

Sponsors

Melanoma Institute Australia

Conditions

Cutaneous Squamous Cell CarcinomaMerkel Cell Carcinoma

Phase 2

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

RecruitingNCT06151236

Melanoma Institute AustraliaMerkel Cell Carcinoma

Start: 2024-03-11End: 2034-04-01Target: 20Updated: 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

RecruitingNCT06288191

Melanoma Institute AustraliaCutaneous Squamous Cell Carcinoma

Start: 2024-06-21End: 2036-07-01Target: 20Updated: 2026-07-08

Related Papers

A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC).

Journal of Clinical Oncology2025-05-28

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

Journal of Clinical Oncology2024-06-011 citations